Abstract:
Currently, four vaccines for COVID-19 have been licensed by the European Medicines Agency: two viral vector-based vaccines and two mRNA-based vaccines. Since their approval, several cutaneous reactions related to vaccination have been reported in the literature. Among these, viral reactivations are one of the most frequent. The aim of this article was to investigate the current literature regarding viral reactivations following COVID-19 vaccination, focusing attention on pityriasis rosea (PR), herpes zoster and herpes simplex. A comprehensive literature search using various databases was performed and we included metanalyses, reviews, letters to the editor, real-life studies, case series and reports. A total of 48 articles involving 2067 patients were selected. Of these, 32, 6 and 17 articles reported varicella zoster virus (VZV) reactivation (1758 patients), herpes simplex virus (HSV) (238 patients) onset and PR (71 patients), respectively (some articles discussed more than one of these three reactivations). Possible pathogenetic mechanisms underlying viral reactivation are still not understood. Also, the possible correlations between vaccination and viral reactivation should be clarified. Certainly, vaccination should not be discouraged.
摘要:
背景:目前,四种COVID-19疫苗已获得欧洲医学机构的许可:基于病毒载体的疫苗(阿斯利康;AZD1222和强生;Ad26。COV2.和2种基于mRNA的疫苗(Pfizer/BioNTech;BNT162b2和Moderna;mRNA-1273)。自从他们批准,文献中已经报道了几种与疫苗接种相关的皮肤反应.其中,病毒的再激活是最常见的。
目的:本手稿的目的是调查目前有关COVID-19疫苗接种后病毒再激活的文献,把注意力集中在玫瑰糠疹上,带状疱疹和单纯疱疹。
方法:使用各种数据库进行全面的文献研究,包括元分析,重新查看,给编辑的信,现实生活中的研究,案例系列,和报告,已执行。
结果:共选择了47篇文章,涉及约2000名患者。其中,32、6和17篇文章报告了VZV重新激活(1,758例),HSV(238例)发作和PR(71例),分别。
结论:病毒再激活可能的致病机制尚不清楚,疫苗接种和病毒再激活之间可能的相关性应该得到澄清。当然,接种疫苗不应该被阻止。